SB 14 creates a new section of Kentucky law governing pharmaceutical manufacturers and 340B drug pricing. The bill defines key terms such as “340B covered entity,” “340B price,” and “covered drug,” tying those definitions to the federal 340B Drug Pricing Program. It then prohibits manufacturers from discriminating against a 340B covered entity by refusing or withholding 340B pricing for a covered drug if the manufacturer offers that same drug at a 340B price in any other state.
The bill also bars manufacturers from imposing conditions, limitations, or delays on the sale or purchase of covered drugs at 340B pricing unless those restrictions are expressly required by federal or state law. It allows a person who believes a manufacturer is violating the section to file a complaint with the Attorney General, who may investigate under existing authority, and it preserves any private right of action. The bill includes a savings clause stating that it should not be interpreted to conflict with or be less restrictive than other federal or state law.
Impact
SB 14 would add a new state-level enforcement mechanism and anti-discrimination rule for the 340B drug pricing program, affecting pharmaceutical manufacturers that sell covered drugs in Kentucky. It would expand protections for 340B covered entities, including eligible health care facilities and their contract pharmacies, by requiring access to 340B pricing when that pricing is offered elsewhere and by limiting manufacturer-imposed barriers. The bill also gives the Attorney General a role in investigating complaints, potentially increasing state oversight of manufacturer conduct in the 340B market.
Sentiment
The available voting history suggests the bill had generally favorable support in the Senate, passing third reading by a 33-4 vote. No committee transcripts are available, so there is no recorded debate to indicate detailed public arguments or amendments. The strong vote margin indicates broad support, though not unanimous, for the bill’s approach to protecting 340B pricing access.
Contention
The main point of contention is likely the bill’s restriction on pharmaceutical manufacturers’ ability to set conditions or limit access to 340B pricing, which could be viewed by manufacturers as an intrusion into pricing and distribution practices. Supporters would likely emphasize protecting safety-net providers and contract pharmacies from discriminatory treatment, while opponents may argue the bill could create compliance burdens or conflict with federal 340B administration. The four dissenting Senate votes suggest some concern remained, but the record provided does not identify specific objections.